Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 12
Anti-vascular endothelial growth factor treatment in diabetic macular edema
Authors Kim M
Received 29 July 2016
Accepted for publication 3 August 2016
Published 2 September 2016 Volume 2016:12 Pages 1355—1356
DOI https://doi.org/10.2147/TCRM.S118460
Checked for plagiarism Yes
Editor who approved publication: Professor Garry Walsh
Moosang Kim
Department of Ophthalmology, School of Medicine, Kangwon National University, Chuncheon, Korea
We read with great interest the article titled “Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation” by Yan et al.1 We congratulate the authors for this well-organized study and would like to contribute to their findings.
The Early Treatment Diabetic Retinopathy Study demonstrated that focal laser for diabetic macular edema (DME) effectively halved the percentage of eyes that experienced vision loss and doubled the percentage of eyes that achieved visual gain.2 Until the past decade, focal laser photocoagulation was the standard of care for treating DME.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.